![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication October 9, 2007.
Revised December 2, 2007.
Accepted for publication December 3, 2007.
The in vitro metabolism of LC15-0133, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, was investigated using a hepatic microsomal system. The structures of the metabolites were characterized using mass spectral analysis and by comparison with synthetic references. The in vitro incubation of LC15-0133 with rat liver microsomes resulted in the formation of six metabolites, with the major metabolic reactions being hydroxylation and carbonyl reduction. Of the metabolites, a C-demethylated metabolite (M4) was identified, but was only detected in rat liver microsomes; experimental evidence revealed that the C-demethylated metabolite was generated by non-enzymatic decarboxylation of the carboxyl metabolite (M1). Non-enzymatic decarboxylation is postulated to occur due to the resonance stabilization by the oxadiazole ring attached to the tert-butyl moiety.
Key words:
enzyme mechanism, metabolite identification, P450 mechanism, structure elucidation
This article has been cited by other articles:
![]() |
C. Prakash, W. Wang, T. O'Connell, and K. A. Johnson CYP2C8- and CYP3A-Mediated C-Demethylation of (3-{[(4-tert-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry-Nuclear Magnetic Resonance Drug Metab. Dispos., October 1, 2008; 36(10): 2093 - 2103. [Abstract] [Full Text] [PDF] |
||||